Breaking Finance News

A statement released earlier today by Shore Capital about AstraZeneca PLC (LON:AZN) bumps the target price to 4,800.00GBX

Boasting a price of 5,205.50GBX, AstraZeneca PLC (LON:AZN) traded 1.10% higher on the day. With the last stock price close up 15.57% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. AstraZeneca PLC has recorded a 50-day average of 4,769.88GBX and a two hundred day average of 4,543.64GBX. Volume of trade was down over the average, with 2,102,285 shares of AZN changing hands under the typical 2,339,870

Shore Capital upped the price target of AstraZeneca PLC (LON:AZN) to 4,800.00GBX indicating a possible downside of -0.08%.

On 5/15/2017, Deutsche Bank released a statement for AstraZeneca PLC (LON:AZN) bumped up the target price from 5,350.00GBX to 5,700.00GBX that suggested an upside of 0.15%.

Performance Chart

AstraZeneca PLC (LON:AZN)

With a total market value of 0 GBX, AstraZeneca PLC has price-earnings ratio of 19.67 with a one year low of 3,680.00GBX and a one year high of 5,505.00GBX .

A total of 29 analysts have released a report on AstraZeneca PLC. Four brokers rating the stock a strong buy, 14 brokers rating the stock a buy, 13 brokerages rating the stock a hold, 2 firms rating the stock a underperform, and finally 1 firm rating the stock a sell with a average stock price target of 61.96GBX.

General Information About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.